Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

The Lancet Haematology - Tập 6 - Trang e132-e143 - 2019
Javier Bolaños-Meade1,2, Ran Reshef3, Raphael Fraser4, Mingwei Fei4, Sunil Abhyankar5, Zaid Al-Kadhimi6, Amin M Alousi7, Joseph H Antin8, Sally Arai9, Kate Bickett10, Yi-Bin Chen11, Lloyd E Damon12, Yvonne A Efebera13, Nancy L Geller14, Sergio A Giralt15, Parameswaran Hari16, Shernan G Holtan, Mary M Horowitz16, David A Jacobsohn17, Richard J Jones1,18,2
1Department of Oncology, Johns Hopkins University, Baltimore, MD USA
2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
3Department of Medicine, Columbia University Medical Center, New York, NY, USA
4Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA
5Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS, USA
6Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
7Department of Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
8Department of Medicial Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
9Department of Medicine, Stanford University, Palo Alto, CA, USA
10The EMMES Corporation, Rockville, MD, USA
11Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
12Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
13Department of Internal Medicine, The Ohio State University Columbus, OH, USA.
14Office of Biostatistics Research, National Institutes of Health, Bethesda, MD, USA
15Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
16Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
17Department of Pediatrics at George Washington University, Children's National Medical Center, Washington, DC, USA
18Department of Medicine, Johns Hopkins University, Baltimore, MD, USA

Tài liệu tham khảo

Zeiser, 2017, Acute graft-versus-host disease—biologic process, prevention, and therapy, N Engl J Med, 377, 2167, 10.1056/NEJMra1609337 Bolaños-Meade, 2004, Acute graft-versus-host disease, Clin Adv Hematol Oncol, 2, 672 Bolaños-Meade, 2008, Chronic graft-versus-host disease, Curr Pharm Des, 14, 1974, 10.2174/138161208785061373 Storb, 1986, Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia, N Engl J Med, 314, 729, 10.1056/NEJM198603203141201 Jagasia, 2012, Risk factors for acute GVHD and survival after hematopoietic cell transplantation, Blood, 119, 296, 10.1182/blood-2011-06-364265 Ratanatharathorn, 1998, Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation, Blood, 92, 2303 Nash, 2000, Phase 3 study comparing methotrexate and tacrolimus with methotrexate and for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors, Blood, 96, 2062 Brunstein, 2007, Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease, Blood, 110, 3064, 10.1182/blood-2007-04-067215 Cutler, 2014, Tacrolimus/sirolimus vs tacrolimus/methotrexate as GvHD prophylaxis after matched, related donor allogeneic HCT, Blood, 124, 1372, 10.1182/blood-2014-04-567164 Martin, 1991, A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment, Blood, 77, 1821, 10.1182/blood.V77.8.1821.1821 Sun, 2004, Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib, Proc Natl Acad Sci USA, 101, 8120, 10.1073/pnas.0401563101 Koreth, 2009, Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors, Blood, 114, 3956, 10.1182/blood-2009-07-231092 Koreth, 2012, Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation, J Clin Oncol, 30, 3202, 10.1200/JCO.2012.42.0984 Murai, 2003, Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction, Nat Immunol, 4, 154, 10.1038/ni879 Murai, 1999, Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease, J Clin Invest, 104, 49, 10.1172/JCI6642 Moy, 2017, Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis, Blood, 129, 906, 10.1182/blood-2016-08-735076 Reshef, 2012, Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease, N Engl J Med, 367, 29, 10.1056/NEJMoa1201248 Kanakry, 2013, Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide, Sci Transl Med, 5, 211ra157, 10.1126/scitranslmed.3006960 Kasamon, 2017, Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide, Blood Adv, 1, 288, 10.1182/bloodadvances.2016002766 Luznik, 2010, High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease, Blood, 115, 3224, 10.1182/blood-2009-11-251595 Luznik, 2008, HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide, Biol Blood Marrow Transplant, 14, 641, 10.1016/j.bbmt.2008.03.005 Pasquini, 2018, Blood and Marrow Transplant Clinical Trials Network report on the development of novel endpoints and selection of promising approaches for graft-versus-host disease prevention trials, Biol Blood Marrow Transplant, 24, 1274, 10.1016/j.bbmt.2018.01.002 Pasquini, 2014, 2013 Report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplant for blood and bone marrow disorders, 187 Przepiorka, 1995, 1994 consensus conference on acute GVHD grading, Bone Marrow Transplant, 15, 825 Filipovich, 2005, National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report, Biol Blood Marrow Transplant, 11, 945, 10.1016/j.bbmt.2005.09.004 Brunstein, 2011, Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts, Blood, 118, 282, 10.1182/blood-2011-03-344853 Kanakry, 2014, Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS, Blood, 124, 3817, 10.1182/blood-2014-07-587477 Kanakry, 2013, Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis, Biol Blood Marrow Transplant, 19, 1514, 10.1016/j.bbmt.2013.07.013 Kanakry, 2017, Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide, Blood, 129, 1389, 10.1182/blood-2016-09-737825 Majzner, 2017, Post-transplantation cyclophosphamide after bone marrow transplantation is not associated with an increased risk of donor-derived malignancy, Biol Blood Marrow Transplant, 23, 612, 10.1016/j.bbmt.2016.12.640 Ho, 2009, Comparison of tacrolimus and sirolimus (Tac/Sir) versus tacrolimus, sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation, Biol Blood Marrow Transplant, 15, 844, 10.1016/j.bbmt.2009.03.017 Finke, 2009, Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial, Lancet Oncol, 10, 855, 10.1016/S1470-2045(09)70225-6 Anasetti, 2012, Peripheral-blood stem cells versus bone marrow from unrelated donors, N Engl J Med, 367, 1487, 10.1056/NEJMoa1203517 Bolaños-Meade, 2012, HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease, Blood, 120, 4285, 10.1182/blood-2012-07-438408
Thông tin
Thông tin xuất bản

The Lancet Haematology

Tập 6

e132-e143

Thông tin tác giả